The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Berberine binds RXRα to suppress β-catenin signaling in colon cancer cells
Open accessAbstract
Berberine, an isoquinoline alkaloid, is a traditional oriental medicine used to treat diarrhea and gastroenteritis. Recently, we reported that it could inhibit the growth of intestinal polyp in animals and in patients with the familial adenomatous polyposis by downregulating β-catenin signaling. However, the intracellular target mediating the effects of berberine remains elusive. Here, we provide evidence that berberine inhibits β-catenin function via directly binding to a unique region comprising residues Gln275, Arg316 and Arg371 in nuclear receptor retinoid X receptor alpha (RXRα), where berberine concomitantly binding to and synergistically activating RXRα with 9-cis-retinoic acid (9-cis-RA), a natural ligand binding to the classical ligand-binding pocket of RXRα. Berberine binding promotes RXRα interaction with nuclear β-catenin, leading to c-Cbl mediated degradation of β-catenin, and consequently inhibits the proliferation of colon cancer cells. Furthermore, berberine suppresses the growth of human colon carcinoma xenograft in nude mice in an RXRα-dependent manner. Together, our study not only identifies RXRα as a direct protein target for berberine but also dissects their binding mode and validates that berberine indeed suppresses β-catenin signaling and cell growth in colon cancer via binding RXRα, which provide new strategies for the design of new RXRα-based antitumor agents and drug combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes
Laffitte, B. A., Repa, J. J., Joseph, S. B., Wilpitz, D. C., Kast, H. R., Mangelsdorf, D. J., & Tontonoz, P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.507 · Cited by 683
Interaction of Nuclear Receptors with the Wnt/β-Catenin/Tcf Signaling Axis: Wnt You Like to Know?
Mulholland, D. J., Dedhar, S., Coetzee, G. A., & Nelson, C. C. (2005) · Endocrine Reviews · doi:10.1210/er.2003-0034 · Cited by 377
Cited by
Biological properties and clinical applications of berberine
Song, D., Hao, J., & Fan, D. (2020) · Frontiers of Medicine · doi:10.1007/s11684-019-0724-6 · Cited by 496
SIRT1 Activation by Natural Phytochemicals: An Overview
Iside, C., Scafuro, M., Nebbioso, A., & Altucci, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01225 · Cited by 307
Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review
Zhang, C., Sheng, J., Li, G., Zhao, L., Wang, Y., Yang, W., Yao, X., Sun, L., Zhang, Z., & Cui, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01461 · Cited by 102
Wu, Y., Chen, Q., Wen, B., Wu, N., He, B., & Chen, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640758 · Cited by 54
Metadata
- Authors
- Ruan, H., Zhan, Y. Y., Hou, J., Xu, B., Chen, B., Tian, Y., Wu, D., Zhao, Y., Zhang, Y., Chen, X., Mi, P., Zhang, L., Zhang, S., Wang, X., Cao, H., Zhang, W., Wang, H., Li, H., Su, Y., Zhang, X. K., & Hu, T.
- Venue
- Oncogene
- Published
- 2017-08-28
- Volume
- 36
- Issue
- 50
- Pages
- 6906-6918
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2746036157
- Cited by
- 158
- References
- 3
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Berberine binds RXRα to suppress β-catenin signaling in colon cancer cells. https://app.cochat.ai/papers/10.1038/onc.2017.296
- The paper
- Ruan, H., Zhan, Y. Y., Hou, J., Xu, B., Chen, B., Tian, Y., Wu, D., Zhao, Y., Zhang, Y., Chen, X., Mi, P., Zhang, L., Zhang, S., Wang, X., Cao, H., Zhang, W., Wang, H., Li, H., Su, Y., . . . Hu, T. (2017). Berberine binds RXRα to suppress β-catenin signaling in colon cancer cells. Oncogene. https://doi.org/10.1038/onc.2017.296
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.